Results of U.S. Joint Clinical Trial on Proton Therapy Funded by Hitachi High-Tech Published
Tokyo, December 17, 2025 — Hitachi High-Tech Corporation ("Hitachi High-Tech"), today announced that the publication of results from a U.S. based Phase III randomized clinical trial comparing Intensity-Modulated Proton Therapy (IMPT) and Intensity-Modulated Radiation Therapy (IMRT). The study was conducted by a consortium of leading institutions led by The University of Texas MD Anderson Cancer Center, with research funding provided by Hitachi High-Tech. The published findings confirm that IMPT demonstrated non-inferiority compared to IMRT.
The announcement by The University of Texas MD Anderson Cancer Center:
Publication Date: December 11, 2025
Hitachi High-Tech will continue contributing to "Create a society without fear of cancer" by offering minimally invasive and cost-effective particle therapy tailored to each patient and aims to contribute to improving and maintaining patients' Quality of Life (QoL) and advancing cancer treatment.
Related Link
Contact Form